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Background: Venous leg ulcers are a major cause of morbidity, economic loss, and decreased quality of life in affected
patients. Recently, biomaterials derived from natural tissue sources have been used to stimulate wound closure. One such
biomaterial obtained from porcine small-intestine submucosa (SIS) has shown promise as an effective treatment to
manage full-thickness wounds. Our objective was to compare the effectiveness of SIS wound matrix with compression vs
compression alone in healing chronic leg ulcers within 12 weeks.
Methods: This was a prospective, randomized, controlled multicenter trial. Patients were 120 patients with at least 1
chronic leg ulcer. Patients were randomly assigned to receive either weekly topical treatment of SIS plus compression
therapy (n 62) or compression therapy alone (n 58). Ulcer size was determined at enrollment and weekly throughout
the treatment. Healing was assessed weekly for up to 12 weeks. Recurrence after 6 months was recorded. The primary
outcome measure was the proportion of ulcers healed in each group at 12 weeks.
Results: After 12 weeks of treatment, 55% of the wounds in the SIS group were healed, as compared with 34% in the
standard-care group (P  .0196). None of the healed patients treated with SIS wound matrix and seen for the 6-month
follow-up experienced ulcer recurrence.
Conclusions: The SIS wound matrix, as an adjunct therapy, significantly improves healing of chronic leg ulcers over
compression therapy alone. (J Vasc Surg 2005;41:837-43.)Venous leg ulcers affect up to 2.5 million patients per
year in the United States and are a major cause of morbidity
and decreased quality of life.1,2 Whereas current methods
of compressive care have reported ulcer healing rates of 68%
to 83% within 24 weeks,3,4 12-week healing rates are more
commonly only 34% to 42%.2,5-7 Many ulcers heal but then
recur at a 12-month rate of 26% to 28%.2
The current standard of care for chronic venous ulcers
involves the use of compression bandages as a means to
reduce ambulatory venous pressure, control edema, and
improve venous return.8,9 When these conservative meth-
ods prove ineffective, surgical intervention is used to either
directly address venous reflux or manage the ulcer through
skin grafting.2 Leg ulcers that fail to heal quickly or that
recur rapidly are often refractory to conservative compres-
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doi:10.1016/j.jvs.2005.01.042sion therapy and may lead to costly hospitalizations or
excessive use of home health-care resources, estimated as
high as $2200 per ulcer per month.10
Recent biotechnologic advances have developed alter-
native therapies for the treatment of chronic wounds.
Rather expensive skin substitutes or more cost-effective
biomaterials derived from natural extracellular matrix
(ECM) can be used to stimulate wound closure.11,12 These
materials promote granulation and epithelialization of der-
mal wounds, effectively regulate evaporation and exuda-
tion, and help to protect the wound site from bacterial
infection. One natural ECMwound-care product, a bioma-
terial derived from the pig small-intestine submucosa (SIS),
has been extensively evaluated in preclinical models and
also applied in the clinical setting since its first description in
1989.13 This thin, translucent layer of the intestine is
approximately 0.15 mm thick and consists primarily of a
collagen-based ECM. However, unlike purified collagen
wound-care products, biologically important components
of the ECM, such as glycosaminoglycans (eg, hyaluronic
acid),14 proteoglycans, fibronectin,15 and growth factors
such as basic fibroblast growth factor16,17 and transforming
growth factor 18 are retained in active forms in the SIS
matrix.
This clinical trial was designed to test the hypothesis
that chronic full-thickness leg ulcers treated with the SIS
wound matrix in addition to standard care would lead to a
greater proportion of healed ulcers at 12 weeks when
compared with standard care alone. This study is the first
complete randomized human clinical trial to assess the
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full-thickness chronic leg ulcers.
METHODS
SIS Wound Matrix. The SIS Wound Matrix (OASIS
Wound Matrix, Healthpoint Ltd, Ft Worth, Tex) is a
naturally occurring ECM derived from the submucosal
layers of the porcine jejunum. Porcine small intestine is
subjected to manufacturing processes that render the ma-
terial free of viral contaminants and minimize the risk of
animal-to-human disease transmission (described else-
where).19 The SIS is freeze-dried and sterilized with ethyl-
ene oxide gas in preparation for clinical use.
Study design. This prospective, randomized, con-
trolled clinical trial, conducted at 12 outpatient sites, was
originally designed to enroll 180 patients to detect a 20%
difference in 12-week healing of SIS wound matrix–treated
patients vs standard of care. Because of delays in patient
accrual, the study population was limited to enrollment of
120 patients. Patients older than 18 years who met all entry
Table I. Summary of patient inclusion criteria
Characteristic Inclusion criteria
Patient age (y) 18 y
Ulcer size (cm2) 1-64
Ulcer depth Extends through both the epidermis and
dermis, with no exposed tendon or
bone
Ulcer duration (mo) 1 mo
Ulcer location Between and including the knee and
ankle
Wound bed
characteristics
Viable wound bed with granulation
tissue
Table II. Summary of patient exclusion criteria
● Exposed bone, tendon, or fascia
● Severe rheumatoid arthritis
● History of radiotherapy to the ulcer site
● Uncontrolled congestive heart failure
● Receiving corticosteroids or immune suppressives
● History of collagen vascular disease
● Malnutrition (albumin 2.5 g/dL)
● Known allergy to porcine-derived products
● Received treatment with any other investigational drug or
device within the last 30 days
● Ulcer clinically infected
● Uncontrolled diabetes (HgbA1c 12%)
● Previous organ transplantation
● Religious or cultural objection to the use of porcine products
● Undergoing hemodialysis
● Signs of cellulitis, osteomyelitis, or necrotic or avascular ulcer
beds
● Ankle-brachial index 0.80
● Active sickle cell disease
● Unable to comply with the procedures described in the
protocol
● Enrolled in a clinical evaluation for another investigational
wound-care device or drug
HgbA1c, Baseline glycosylated hemoglobin.criteria were randomly assigned to receive either the controltreatment (wound cleansing, débridement [as necessary],
dressing changes, and compression therapy) or application
of the SIS wound matrix in addition to the control treat-
ment. Patients were observed for up to 12 weeks. Patients
in the standard-care arm were given the option of crossover
treatment with SIS if healing did not occur. A 6-month
follow-up visit was also requested.
Study population. This trial was conducted in the
United States, United Kingdom, and Canada under the
direction of International Conference on Harmonization
E6 Good Clinical Practice guidelines. The study protocol
and informed consent statements were reviewed and ap-
proved by either an independent institutional review board
or each location’s governing institutional review board or
ethics committee. Prospective patients with chronic venous
insufficiency (according to clinical presentation and his-
tory), positive venous reflux, or both; who met the addi-
tional criteria presented in Table I; and who signed in-
formed consent were considered for inclusion. Criteria for
exclusion are listed in Table II.
Patients whomet the inclusion criteria were required to
undergo a 2-week screening period before enrollment.
During the screening period, the target ulcer was treated
with standard care and compression therapy. Ulcers that
exhibited a greater than 50% reduction in surface area
during the screening period were excluded from the trial to
ensure that the patients enrolled had chronic leg ulcers not
adequately responding to conventional therapy. At the
completion of the 2-week screening period, eligible pa-
tients were randomized to one of the two treatment groups
by using a centralized computer system with a block size of
four. Investigators were blinded to this randomization
scheme to eliminate bias and, upon contacting the com-
puter system, received an automatic faxed confirmation
that indicated the patient’s assigned group and unique
enrollment number.
Protocol and evaluations. The SIS wound matrix
group received a piece of the SIS applied directly to the
wound bed, followed by the application of a nonadherent
dressing (Allevyn; Smith & Nephew, Largo, Fla) and a
four-layer compression bandaging system (Profore; Smith
& Nephew) to maintain direct contact of the SIS wound
matrix with the wound bed and to further protect the
healing environment. To apply the SIS wound matrix, the
ulcer was routinely cleaned by using gentle irrigation with
sterile saline, and the SIS was cut to size slightly larger than
the ulcer, placed on the wound bed, and moistened with
sterile saline. The standard-care group received an identical
nonadherent dressing and four-layer compression bandag-
ing system, but no SIS. During the treatment period, all
wounds were evaluated weekly. During these follow-up
visits, patients in both treatment groups received wound
cleansing, débridement (as clinically necessary at the discre-
tion of the investigator), dressing changes, and compres-
sion therapy. Ulcer dimensions were documented by mea-
suring the length and width of the ulcer (length was the
longest edge-to-edge measurement of the ulcer, and width
was the longest ulcer dimension perpendicular to the
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applications of SIS occurred at the weekly evaluation visits,
determined as needed by the clinician. SIS was reapplied to
the entire nonepithelialized portion of the wound during
these visits. The amount of SIS used and the number of
dressing changes performed was recorded for each patient
on the case report forms.
Patients in the standard-care group whose wounds did
not heal by the 12th week were given the option to receive
SIS crossover treatment for 4 weeks and up to an additional
8 weeks if the target ulcer showed responsiveness to the SIS
in the first month after crossover (wound size had to
decrease by 50% in the first 4 weeks). No standardized
regimen was recommended after the study treatment pe-
riod; however, efforts were made to see all patients at a final
6-month follow-up visit to determine the durability of ulcer
closure.
Demographic and baseline data collected included pa-
tient sex, race, age, weight, height, baseline glycosylated
hemoglobin, baseline albumin, and patient location (out-
patient or home-care setting). Baseline ulcer information
included ulcer location, duration, status (new or recurrent),
and surface area. Baseline medical history information in-
cluded patient status on each of the following: diabetes,
hypertension, endocrine disease, immunosuppression,
Alzheimer disease, connective tissue disease, musculoskel-
etal disease, peripheral vascular disease, and dementia. In
addition, baseline levels of granulation tissue and avascular
tissue, along with the baseline débridement status and the
amount of drainage, were recorded. Baseline characteristics
were used as covariates in the final statistical analysis to
judge their influence on treatment success.
After treatment initiation, patients were evaluated
weekly for up to 12 weeks for healing and complications.
The primary outcome measure of the study was prospec-
tively defined as the incidence of complete wound healing
by 12 weeks, defined as full epithelialization of the wound
with the absence of drainage. The time to healing was
computed as the treatment period day during the weekly
visit at which the surface area of the wound was noted as
zero and completely healed. Adverse events were noted on
the case report forms and were recorded at each visit.
Statistical analysis. Study data were collected and
entered into a study database by a contract research orga-
nization (MED Institute, West Lafayette, Ind) by using
quality-control procedures. A quality-assurance check of
the database datasets vs the case report forms was per-
formed. The database was transferred to a statistical services
company (STATKING Consulting, Inc, Fairfield, Ohio)
for independent analysis. All statistical analyses were per-
formed with SAS software (version 8.2 for Windows; SAS
Inc, Cary, NC) on the intent-to-treat population.
The frequency of wound healing at 12 weeks in the SIS
wound matrix and standard-care treatment groups was
analyzed by using the Fisher exact test at the one-sided  
.05 level of significance. Healing data were re-examined by
using baseline demographics and wound characteristics ascovariates. All of these tests were conducted at the two-
sided   .05 level of significance.
The difference in healing proportions, adjusting for
each of the potential covariates, was tested with the
Cochran-Mantel-Haenszel test and the Breslow-Day test of
the homogeneity of odds ratios across strata. Time to
healing was examined by using a Cox proportional hazards
regression model.
Continuous demographic and baseline variables were
compared by using analysis of variance. A 2 test was used
to compare categorical demographic and baseline variable
response profiles. The Fisher exact test was used to compare
the proportion of patients in each treatment group who
experienced adverse events.
RESULTS
Patients. There were no differences between the stan-
dard-care and SIS wound matrix groups with respect to
patient demographics and baseline ulcer size and duration
(Table III). The mean ulcer size in the SIS wound matrix
group was 10.2 cm2, as compared with 12.1 cm2 in the
standard-care group (P .4580), and themedian ulcer size
in the SIS wound matrix group was 6.75 cm2, vs 5.12 cm2
in the standard-care group. The incidence of patients with
an ulcer duration longer than 3 months was 61% in the SIS
wound matrix group (34% for 1 year) and 64% in the
standard-care group (40% for 1 year). Overall, 10% of
patients treated used home care, and 89% were treated on
Table III. Selected patient and wound baseline
demographics
Variable
SIS Wound
Matrix (n  62) Control (n  58)
Age (y)
Mean  SEM 63  2 65  2
Range 21-90 36-93
Sex, n (%)
Male 29 (47%) 21 (36%)
Female 33 (53%) 37 (64%)
BMI (kg/m2)
Mean  SD 32.9  10.6 30.9  10.3
Range 19-80 18-78
Race, n (%)
White 51 (82%) 46 (79%)
Black 10 (16%) 9 (16%)
Asian 0 (0%) 1 (2%)
Other 1 (2%) 2 (3%)
Ulcer duration, n (%)
1-3 mo 23 (37%) 18 (31%)
4-6 mo 12 (19%) 7 (12%)
7-12 mo 5 (8%) 7 (12%)
1 y 21 (34%) 23 (40%)
Not specified 1 (2%) 3 (5%)
Ulcer area (cm2)
Mean  SEM 10.2  1.51 12.1  1.98
Median 6.75 5.12
Range 1.05-58.8 1.15-57.8
SIS, Small-intestine submucosa; BMI, body mass index.an outpatient basis.
throu
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wound matrix arm and 12 in the standard-care arm—did
not complete the planned 12-week follow-up for reasons
other than ulcer healing. These patients were included in
the data analysis within their assigned group. Patient flow
throughout the study and the reasons for study noncom-
pletion are displayed in Fig 1.
Incidence of healing. Results at the end of the 12-
week treatment period showed that healing occurred in
55% (34/62) of patients who received SIS wound matrix
plus standard care vs 34% (20/58) of patients who received
standard care alone (P  .0196), thus indicating statistical
superiority. An odds ratio calculation indicated that pa-
tients receiving SIS were 2.3 times more likely to have
complete wound healing as compared with patients receiv-
ing standard care alone (odds ratio, 2.307). In addition to
dressing changes during the weekly visits, patients in the
SIS wound matrix group had an average of 1.8 dressing
changes during the treatment period, compared with 3.4
for the standard-of-care group. On average, eight 3 
7-cm2 sheets of SIS were used per patient in the SIS group
during the treatment period.
Time to healing. The Cox proportional hazards re-
gression analysis showed an estimated probability of suc-
Fig 1. Patient flowcessful healing of 63% at 12 weeks for the SIS woundmatrixgroup and 40% for the standard-care group. A significant
difference between the survival curves for the two groups
(P  .0226) was indicated (Fig 2).
Covariate analysis. The covariate analyses indicated
that patients in the SIS wound matrix group maintained a
consistent or greater proportion of healing, even when
taking into account the presence of comorbidities such as
vascular disease (P  .0253), type 2 diabetes (P  .0214),
endocrine disease (P  .0272), and hypertension (P 
.0204). Similarly, this analysis also showed that after adjust-
ing for baseline ulcer size, patients in the SIS group were 3
times more likely to achieve healing than those in the
standard-care group (P  .0067; odds ratio, 2.996).
Further covariate analysis also indicated that patients in
the SIS wound matrix group maintained a consistent or
greater proportion of healing whether or not baseline
débridement was performed (P  .0215). A subgroup
analysis on débridement status also indicated that when
baseline débridement was performed, patients in the SIS
wound matrix group were 4 times more likely to heal than
those in the standard-care group. Specifically, 19 (63%) of
30 SIS wound matrix patients who had baseline débride-
ment healed, compared with 8 (30%) of 27 in the standard-
gh the clinical trial.care group (P  .0167; odds ratio, 4.10).
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teen patients randomized to the standard-care arm joined
the crossover group treated with the SIS wound matrix.
Five (26%) of the 19 crossover patients healed after receiv-
ing an average of 4 applications of SIS wound matrix.
A total of 54 patients (45%) were seen at a 6-month or
later follow-up visit: 30 in the SIS wound matrix group and
24 in the standard-care group. Of these 54 patients, 29 had
healed ulcers within the 12-week study period of treatment,
and 26 of the 29 study ulcers remained healed at the
6-month follow-up visit: 19 (100%) of 19 in the SIS wound
matrix group and 7 (70%) of 10 in the standard-care group.
Of the other 25 patients with ulcers that did not heal within
the 12-week study period, 5 patients were healed at the
6-month or later follow-up visit (1 of 11 patients in the SIS
wound matrix group and 4 of 14 patients in the standard-
care group). Of the 4 standard-care patients whose wounds
healed later, 3 were patients treated with SIS wound matrix
as part of the crossover group.
Adverse events. A total of 23 complications were ob-
served (Table IV). There was no significant difference
between the proportions of patients who experienced at
least one adverse event during the study in the two treat-
ment groups (P  .1920). There was no significant differ-
ence between the proportions of patients who experienced
infection-related adverse events in the two treatment
Fig 2. Survival plot analysis for the small-intestine submucosa
(SIS) wound matrix group and the standard-care group. Success
was defined as 100% healing. Patients treated with SIS wound
matrix were more likely to heal by 12 weeks than those in the
standard-care group (P  .0226).groups (P .2611). One (1.6%) of 62 patients had a targetulcer infection-related adverse event in the SIS wound
matrix group, whereas 5 (8.6%) of 58 patients had a target
ulcer infection-related adverse event in the standard-care
group (P  .1057).
DISCUSSION
Patients with long-term venous ulcers represent a sub-
group of patients who have failed to respond to standard
available therapies and can be considered to have the most
difficult-to-treat ulcers. For this patient population, alter-
natives to standard compression therapy are essential if
wound closure is to be achieved, especially given that many
patients report difficulty with, noncompliance with, or
intolerance to compression therapy.20 This clinical investi-
gation represents the first multicenter randomized clinical
trial designed to assess the effectiveness of a natural ECM
biomaterial for the treatment of chronic leg ulcers.
Treatment of chronic leg ulcers with the SIS wound
matrix significantly increased the incidence of complete
healing at 12 weeks vs standard care; it showed 62% more
efficacy than standard compression dressing treatments. A
study limitation is potential bias, because blinding of the
investigator and patient was not possible. A further limita-
tion of the study is that the establishment of venous disease
before enrollment was not always confirmed with duplex
imaging, even though all prospective patients had underly-
ing venous disease diagnosed by clinical presentation. The
analysis showed that both groups were matched on all
demographic data and had ulcers of similar chronicity and
size; these variables were therefore eliminated as factors
affecting the observed healing rates.
As noted by Phillips et al,21 baseline ulcer area has been
reported as a prognostic indicator for venous ulcer healing
outcome. After adjusting for a baseline wound size of 5 cm2
or more, the covariate analysis in this study indicated that
patients were three times more likely to heal in the SIS
wound matrix group than were those in the standard-care
group. These data suggest that the SIS wound matrix is
effective in healing chronic leg ulcers regardless of the
baseline ulcer size.
Débridement is also known to be an important consid-
Table IV. Study complications*
Complication
SIS Wound
Matrix
(n  8)
Standard
care
(n  15)
Skin injury 1 1
Allergic reaction or intolerance to
secondary dressing
3 3
Seroma 0 1
New ulcer due to compression 0 1
Health deterioration/hospitalization 1 2
Non–target wound infection 1 1
Wound infection 1 6
Death (due to cardiovascular disease) 1 0
SIS, Small-intestine submucosa.
*P  .1920 between treatment groups.eration in healing venous ulcers,1 and this was corroborated
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showed that when baseline débridement was performed,
patients in the SIS wound matrix group were four times
more likely to heal than were those in the standard-care
group. These data suggest that baseline débridement can
positively influence the healing rates observed when SIS is
used to treat chronic leg ulcers, and it should therefore be
considered as part of a complete treatment program.
The 6-month follow-up analysis revealed that, of the
subset of patients studied, 100% of the SIS wound matrix
patients whose wounds healed within 12 weeks remained
healed 6 months later but that only 70% of the standard-
care treatment wounds that had complete healing remained
closed. This finding is significant in that recurrence rates
after standard compression therapy have been reported to
be at least 26% to 28%3,22 and may be as high as 69%.2,23 It
is important to note that the wounds treated with SIS
wound matrix did not recur during the follow-up period,
and this suggests that chronic leg wounds treated with SIS
in addition to standard care may be less likely to recur than
those treated with compression alone. Clearly, the limited
number of wounds examined at the 6-month follow-up
suggests that additional investigation may be warranted to
definitively determine recurrence after treatment with SIS.
Although treatment costs were not rigorously studied
in this trial, the number of dressing changes was recorded,
as was the average amount of SIS wound matrix applied, to
assess the added costs of using SIS wound matrix vs stan-
dard care. In addition to dressing changes during the
weekly visits, patients in the SIS wound matrix group had
an average of 1.8 dressing changes during the treatment
period, compared with 3.4 for the standard-of-care group.
The average amount of SIS applied per patient was eight
3  7-cm2 sheets, representing a total cost of approxi-
mately $320.00 during the treatment period. Given the
high monthly costs of treating chronic venous ulcers, in-
cluding the relatively expensive multilayer bandage system
for compression, the efficacy shown by SIS in leading to a
greater incidence of healing and in reducing time to healing
vs standard care alone is important in determining the
course of treatment and in reducing overall health-care
costs.
It is our opinion that the SIS wound matrix was easy to
apply, was well tolerated by the patients, and did not induce
any clinically observable adverse immunologic reactions
with repeated application. These observational findings are
consistent with other reports that have shown that the SIS
wound matrix does not cause antibody formation in leg
ulcer patients, even after repeated application.24 These
observations and clinical findings are consistent with the
known properties of the SIS biomaterial, support preclini-
cal findings,25-27 and support the initial observations of
effectiveness in humans.11,12
The pathogenesis of venous ulceration remains de-
bated, but regardless of the exact mechanism of venous
ulcer development, it is well established that these ulcers
contain high levels of matrix-degrading enzymes28 and also
fail to contract and epithelialize at the rate of an acutewound in a patient who does not have venous reflux. It has
been suggested, therefore, that active treatment to stimu-
late closure and modulate the wound environment is nec-
essary to stimulate the healing process.1 Standard-care
treatments for venous leg ulcers include weekly wound
cleansing, débridement, dressing changes, and compres-
sion therapy. This standard care has been reported to lead
to healing after 12 weeks in approximately 34% to 40% of
patients.5,6 The standard-care multilayer bandage com-
pression system used in this study led to healing in 34% of
treated wounds, but the addition of SIS woundmatrix as an
adjunct to the standard-care treatment improved the heal-
ing rate to 55%. Unlike purified collagen dressings or
palliative standard-care treatments, the SIS woundmatrix is
an active treatment that stimulates wound closure. SIS
contains a complex composition of active factors known to
stimulate the proliferation and differentiation of various cell
types.14-18 It also stimulates neovascularization in surgical
cases29 and enhances wound contraction and closure in
animal models.25 SIS also contains collagen and heparan
sulfate proteoglycans,30 which sequester matrix metallo-
proteases and other matrix-degrading enzymes31 and pre-
vent them from catabolizing the immature matrix as the
wound heals. Although a definitive link between the com-
position of the SIS wound matrix and its positive effects on
chronic wounds has not been established, the presence of
cell growth and differentiation factors within the matrix
and the matrix’s ability to bind proteases suggest that these
matrix components may be essential to the positive healing
capabilities of this material.
In conclusion, these results demonstrate that within the
setting of a comprehensive wound-management program,
application of the SIS woundmatrix increases the incidence
of complete closure of chronic leg ulcers, speeds the rate at
which healing occurs, and may reduce the incidence of
ulcer recurrence. This suggests that substantial patient ben-
efit can be achieved with the use of SIS wound matrix as an
adjunct to the current standard-of-care treatment.
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